Wall Street brokerages expect that Aduro BioTech Inc (NASDAQ:ADRO) will report earnings of ($0.33) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Aduro BioTech’s earnings. The lowest EPS estimate is ($0.36) and the highest is ($0.29). Aduro BioTech posted earnings of ($0.27) per share during the same quarter last year, which suggests a negative year over year growth rate of 22.2%. The company is expected to report its next earnings report on Wednesday, August 1st.
On average, analysts expect that Aduro BioTech will report full-year earnings of ($1.28) per share for the current fiscal year, with EPS estimates ranging from ($1.50) to ($1.01). For the next financial year, analysts anticipate that the company will report earnings of ($1.08) per share, with EPS estimates ranging from ($1.51) to $0.03. Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for Aduro BioTech.
Aduro BioTech (NASDAQ:ADRO) last released its quarterly earnings results on Wednesday, May 2nd. The biotechnology company reported ($0.28) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.35) by $0.07. Aduro BioTech had a negative net margin of 455.58% and a negative return on equity of 39.00%. The firm had revenue of $6.63 million for the quarter, compared to analyst estimates of $3.88 million.
A number of research firms recently weighed in on ADRO. BidaskClub raised shares of Aduro BioTech from a “hold” rating to a “buy” rating in a research note on Saturday, May 12th. HC Wainwright set a $10.00 target price on shares of Aduro BioTech and gave the company a “buy” rating in a research note on Thursday, May 3rd. ValuEngine downgraded shares of Aduro BioTech from a “sell” rating to a “strong sell” rating in a research note on Friday, April 6th. Finally, Zacks Investment Research downgraded shares of Aduro BioTech from a “buy” rating to a “hold” rating in a research note on Wednesday, March 7th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $13.92.
In other Aduro BioTech news, CEO Stephen T. Isaacs sold 40,000 shares of the stock in a transaction on Wednesday, May 9th. The shares were sold at an average price of $8.01, for a total value of $320,400.00. Following the completion of the sale, the chief executive officer now owns 211,434 shares in the company, valued at $1,693,586.34. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Elsas Andrea Van sold 6,874 shares of the stock in a transaction on Monday, February 26th. The shares were sold at an average price of $6.48, for a total transaction of $44,543.52. Following the completion of the sale, the insider now owns 216,669 shares of the company’s stock, valued at approximately $1,404,015.12. The disclosure for this sale can be found here. Insiders have sold 158,925 shares of company stock valued at $1,332,336 in the last 90 days. 5.00% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently modified their holdings of the company. Legal & General Group Plc increased its position in Aduro BioTech by 105.3% during the first quarter. Legal & General Group Plc now owns 22,233 shares of the biotechnology company’s stock worth $206,000 after acquiring an additional 11,405 shares during the period. Foundry Partners LLC increased its position in Aduro BioTech by 31.4% during the first quarter. Foundry Partners LLC now owns 114,028 shares of the biotechnology company’s stock worth $1,060,000 after acquiring an additional 27,230 shares during the period. Millennium Management LLC increased its position in Aduro BioTech by 329.7% during the first quarter. Millennium Management LLC now owns 1,282,347 shares of the biotechnology company’s stock worth $11,926,000 after acquiring an additional 983,906 shares during the period. Barclays PLC increased its position in Aduro BioTech by 125.1% during the first quarter. Barclays PLC now owns 68,887 shares of the biotechnology company’s stock worth $641,000 after acquiring an additional 38,288 shares during the period. Finally, Sofinnova Ventures Inc bought a new position in Aduro BioTech during the first quarter worth about $155,000. 47.26% of the stock is currently owned by institutional investors.
Shares of ADRO traded down $0.15 on Friday, reaching $7.95. 5,000 shares of the company’s stock were exchanged, compared to its average volume of 539,313. The company has a market cap of $653.46 million, a price-to-earnings ratio of -5.53 and a beta of 2.10. Aduro BioTech has a 12 month low of $8.10 and a 12 month high of $8.35.
About Aduro BioTech
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.